Rural Health
Resources by Topic: Pharmacy and prescription drugs
Screening and Referral Programs for Diabetes and Cardiovascular Disease: Can Community Pharmacists Bridge the Care Gap?
Examines the community-based valued-driven care initiative (CVCI) in community pharmacies to evaluate its effectiveness related to screening and referral (S&R) to treat cardiovascular disease (CVD) and diabetes mellitus (DM). Analyzes patient demographics and success rates of CVD and DM S&R in 6 community pharmacies, with both rural and urban locations represented.
Author(s): Melanie Livet, Amber Watson, Shweta Pathak, et al.
Citation: Exploratory Research in Clinical and Social Pharmacy, 17, 100539
Date: 03/2025
view details
Examines the community-based valued-driven care initiative (CVCI) in community pharmacies to evaluate its effectiveness related to screening and referral (S&R) to treat cardiovascular disease (CVD) and diabetes mellitus (DM). Analyzes patient demographics and success rates of CVD and DM S&R in 6 community pharmacies, with both rural and urban locations represented.
Author(s): Melanie Livet, Amber Watson, Shweta Pathak, et al.
Citation: Exploratory Research in Clinical and Social Pharmacy, 17, 100539
Date: 03/2025
view details
Opioid Use Among Rural Medicare Beneficiaries
Examines trends in prescription opioid use among Medicare beneficiaries in rural areas, utilizing 2010-2017 Medicare Current Beneficiary Survey (MCBS) data. Provides data on receipt of opioid prescriptions among community-dwelling and facility-dwelling beneficiaries, associations between prescribing and chronic overlapping pain conditions (COPCs), and prescriptions exceeding CDC guidelines. Includes rural-urban comparisons.
Author(s): Yvonne Jonk, Heidi O'Connor, Karen Pearson, et al.
Date: 01/2025
Sponsoring organization: Maine Rural Health Research Center
view details
Examines trends in prescription opioid use among Medicare beneficiaries in rural areas, utilizing 2010-2017 Medicare Current Beneficiary Survey (MCBS) data. Provides data on receipt of opioid prescriptions among community-dwelling and facility-dwelling beneficiaries, associations between prescribing and chronic overlapping pain conditions (COPCs), and prescriptions exceeding CDC guidelines. Includes rural-urban comparisons.
Author(s): Yvonne Jonk, Heidi O'Connor, Karen Pearson, et al.
Date: 01/2025
Sponsoring organization: Maine Rural Health Research Center
view details
Community Opioid Overdose Reversal Medications (OORMs) Planning Toolkit
Provides planning and strategy resources for organizations and communities to expand access to naloxone and other opioid overdose reversal medications (OORMs). Includes templates, implementation strategies and program examples, and more. Discusses rural considerations and programs throughout, including the Rural EMS Training Program and Rural Communities Opioid Response Program (RCORP).
Date: 01/2025
Sponsoring organization: Substance Abuse and Mental Health Services Administration
view details
Provides planning and strategy resources for organizations and communities to expand access to naloxone and other opioid overdose reversal medications (OORMs). Includes templates, implementation strategies and program examples, and more. Discusses rural considerations and programs throughout, including the Rural EMS Training Program and Rural Communities Opioid Response Program (RCORP).
Date: 01/2025
Sponsoring organization: Substance Abuse and Mental Health Services Administration
view details
January 2025 MedPAC Meeting Transcript
Transcript from the Medicare Payment Advisory Commission's (MedPAC) January 2025 meeting. Covers payment adequacy and updates for physician and other health professional services, hospital inpatient and outpatient services, skilled nursing facility services, home health agency services, inpatient rehabilitation facility services, outpatient dialysis services, and hospice services. Discusses status reports on Medicare Part D, ambulatory surgical centers, and the Medicare Advantage program, as well as policy options for modifying the cost-sharing liability for beneficiaries who receive care at Critical Access Hospitals. Includes rural references and considerations throughout.
Additional links: Reducing Beneficiary Cost-sharing for Outpatient Services at Critical Access Hospitals
Date: 01/2025
Sponsoring organization: Medicare Payment Advisory Commission
view details
Transcript from the Medicare Payment Advisory Commission's (MedPAC) January 2025 meeting. Covers payment adequacy and updates for physician and other health professional services, hospital inpatient and outpatient services, skilled nursing facility services, home health agency services, inpatient rehabilitation facility services, outpatient dialysis services, and hospice services. Discusses status reports on Medicare Part D, ambulatory surgical centers, and the Medicare Advantage program, as well as policy options for modifying the cost-sharing liability for beneficiaries who receive care at Critical Access Hospitals. Includes rural references and considerations throughout.
Additional links: Reducing Beneficiary Cost-sharing for Outpatient Services at Critical Access Hospitals
Date: 01/2025
Sponsoring organization: Medicare Payment Advisory Commission
view details
Projecting the Impact of the $2,000 Part D Out-Of-Pocket Cap for Medicare Part D Enrollees with High Prescription Drug Spending
Examines the impact of the Medicare Part D $2,000 cap on out-of-pocket prescription drugs. Provides projected savings according to low-income subsidy (LIS) status, state, and demographic characteristics, including urban, rural-micropolitan, rural-other, or unclassified geographic location.
Date: 01/2025
Sponsoring organization: HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Examines the impact of the Medicare Part D $2,000 cap on out-of-pocket prescription drugs. Provides projected savings according to low-income subsidy (LIS) status, state, and demographic characteristics, including urban, rural-micropolitan, rural-other, or unclassified geographic location.
Date: 01/2025
Sponsoring organization: HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Combating Antimicrobial Resistance During the COVID-19 Pandemic: Perceived Risks and Protective Practices
Explores the range of factors that impacted efforts to combat antimicrobial resistance (AMR) during the COVID-19 pandemic. Presents findings from an analysis of published scholarly sources and lessons learned from urban and rural healthcare professionals involved in antimicrobial stewardship. Includes rural references and considerations throughout.
Author(s): Casey Sullivan, Cody R. Fisher, Laurin Grabowsky, et al.
Date: 01/2025
Sponsoring organizations: Eastern Research Group, Inc., HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Explores the range of factors that impacted efforts to combat antimicrobial resistance (AMR) during the COVID-19 pandemic. Presents findings from an analysis of published scholarly sources and lessons learned from urban and rural healthcare professionals involved in antimicrobial stewardship. Includes rural references and considerations throughout.
Author(s): Casey Sullivan, Cody R. Fisher, Laurin Grabowsky, et al.
Date: 01/2025
Sponsoring organizations: Eastern Research Group, Inc., HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Estimating the Effects of the Medicare $2 Drug List on Part D Enrollees
Discusses the Medicare $2 Drug List (M2DL) Model, which would allow Medicare Part D enrollees to purchase monthly drugs for $2 or less. Provides projected financial impact of the model, such as out of pocket (OOP) costs for individual drugs as well as OOP changes for enrollees, with breakdowns by demographic variables, including urban, rural-micropolitan, rural-other, or unclassified location.
Date: 12/2024
Sponsoring organization: HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Discusses the Medicare $2 Drug List (M2DL) Model, which would allow Medicare Part D enrollees to purchase monthly drugs for $2 or less. Provides projected financial impact of the model, such as out of pocket (OOP) costs for individual drugs as well as OOP changes for enrollees, with breakdowns by demographic variables, including urban, rural-micropolitan, rural-other, or unclassified location.
Date: 12/2024
Sponsoring organization: HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Understanding MAT Access in the Context of Unused MAT Capacity in the United States: When Increasing Rural MAT Capacity is Not Enough
Examines the factors related to buprenorphine prescriptions to treat opioid use disorder (OUD) and the impacts of the federal DATA waiver to increase provider capacity. Utilizes multiple data sources to describe medication-assisted treatment (MAT) capacity, access, barriers, availability of MAT, and service area need in rural areas.
Author(s): Carolyn Carpenedo Mun, Rachel Zambrano, Eileen Tallman, et al.
Citation: Substance Abuse Treatment, Prevention, and Policy, 19, 47
Date: 12/2024
view details
Examines the factors related to buprenorphine prescriptions to treat opioid use disorder (OUD) and the impacts of the federal DATA waiver to increase provider capacity. Utilizes multiple data sources to describe medication-assisted treatment (MAT) capacity, access, barriers, availability of MAT, and service area need in rural areas.
Author(s): Carolyn Carpenedo Mun, Rachel Zambrano, Eileen Tallman, et al.
Citation: Substance Abuse Treatment, Prevention, and Policy, 19, 47
Date: 12/2024
view details
Pharmacy-Based Preventive Services for Opioid Use Disorder: A Survey of U.S. Pharmacists
Examines pharmacist perceptions related to addressing opioid use disorder (OUD) and substance use disorder (SUD) in their patients. Utilizes online survey data from 1,146 pharmacists to analyze pharmacist concerns about drug use; drug screenings, interventions, and referrals; and commitment and readiness to address OUD and SUD in their patients. Includes breakdowns of pharmacist demographics as well as rurality of pharmacy locations.
Author(s): Li-Tzy Wu, Jacquie King, Kathryn Hefner, et al.
Citation: Addiction Science & Clinical Practice, 19, 88
Date: 12/2024
view details
Examines pharmacist perceptions related to addressing opioid use disorder (OUD) and substance use disorder (SUD) in their patients. Utilizes online survey data from 1,146 pharmacists to analyze pharmacist concerns about drug use; drug screenings, interventions, and referrals; and commitment and readiness to address OUD and SUD in their patients. Includes breakdowns of pharmacist demographics as well as rurality of pharmacy locations.
Author(s): Li-Tzy Wu, Jacquie King, Kathryn Hefner, et al.
Citation: Addiction Science & Clinical Practice, 19, 88
Date: 12/2024
view details
Texas Cares Rx Annual Program Report
Reports on fiscal year 2024 costs, initiatives, feedback, and future considerations for Texas Cares Rx, a prescription drug cost savings program for uninsured Texans. Pages 9-11 summarize stakeholder feedback on rural health needs, including discussion of rural healthcare access gaps and pharmacy deserts.
Date: 12/2024
Sponsoring organization: Texas Health and Human Services
view details
Reports on fiscal year 2024 costs, initiatives, feedback, and future considerations for Texas Cares Rx, a prescription drug cost savings program for uninsured Texans. Pages 9-11 summarize stakeholder feedback on rural health needs, including discussion of rural healthcare access gaps and pharmacy deserts.
Date: 12/2024
Sponsoring organization: Texas Health and Human Services
view details